A Phase 3 interventional study of Cebranopadol 400 ug in Pain, sponsored by Adneuris Therapeutics, Inc.. Recruiting at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Adneuris Therapeutics, Inc. · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.
2,219 studies on the registry are indexed under Pain; 915 are open to participants now.
This study's planned enrollment of 160 is above the median of 70 across 1,901 interventional studies indexed under Pain.
Browse Pain studies →This is the only study on the registry with Adneuris Therapeutics, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants receive Cebranopadol 400 µg Starting dose 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.
Drug: Cebranopadol 400 ug
Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.
Sum of pain intensity differences through 48 hours (SPID48)
Sum of pain intensity differences through 48 hours (SPID48), calculated from NPRS assessments collected following the first administration of cebranopadol.
Time frame: From 0 through 48 hours
Plan to share: Yes — Only IPD used in the results publication
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.